Related Experiment Videos
An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction
J W Hay1, E H Wittels, A M Gotto
1Hoover Institution, Stanford University 94305-6010.
Insights
Lovastatin therapy for cholesterol lowering in adults aged 35-55 offers cost-effective primary prevention of coronary artery disease (CAD). The cost per life-year saved is favorable, especially for high-risk individuals, compared to other treatments.
Area of Science:
- Cardiovascular Medicine
- Health Economics
- Pharmacoeconomics
Background:
- Coronary artery disease (CAD) is a leading cause of mortality.
- Primary prevention strategies aim to reduce CAD incidence in asymptomatic individuals.
- Cholesterol lowering therapies are a cornerstone of cardiovascular risk management.
Purpose of the Study:
- To evaluate the cost-effectiveness of lovastatin therapy for primary prevention of CAD.
- To analyze the cost per life-year saved for lovastatin in different risk groups.
- To compare lovastatin's economic benefits with alternative hypercholesterolemia treatments.
Main Methods:
- Lifetime lovastatin therapy modeled for adults aged 35-55.
- Framingham Heart Study data used for CAD risk reduction estimates.
- Patient perspective adopted for cost-benefit analysis.
Main Results:
- Cost per life-year saved varied by sex and risk level, ranging from $6,000 to $297,000.
- Lovastatin therapy demonstrated favorable cost-effectiveness compared to previous studies.
- At least 800,000 Americans aged 35-55 are candidates for cost-effective lovastatin intervention.
Conclusions:
- Lovastatin therapy is a cost-effective strategy for primary prevention of CAD in adults.
- The economic benefits are particularly pronounced in high-risk populations.
- Lovastatin's net cost is favorable when compared to other widely used medical interventions.
Abstract:
The costs and benefits of cholesterol lowering in the primary prevention of coronary artery disease (CAD) were considered using lifetime lovastatin therapy as the intervention model for adults between 35 and 55 years of age. The analysis projected the benefits of CAD risk reduction using estimates from the Framingham Heart Study. The chosen analytic perspective was that of the patient. For average-risk men with total serum cholesterol levels between 5.69 and 9.83 mmol/liter (220 and 380 mg/dl), the cost per life-year saved ranged from $9,000 to $106,000, whereas for average-risk women, the cost ranged from $35,000 to $297,000 (1989 U.S. dollars). In high-risk men (with smoking habit and hypertension), the cost per life-year saved values ranged from 6,000 to $53,000, whereas in high-risk women the cost per life-year saved values ranged from $19,000 to $160,000. The results were more favorable than those found in previous studies of alternate medication therapies for hypercholesterolemia. Even using conservative parameter assumptions, at least 800,000 Americans aged 35 to 55 years are at sufficiently high risk for CAD, so that the net cost of lovastatin therapy can be favorably compared with other widely used medical interventions.